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Abstract 
Purpose: Post-implant dosimetry following prostate seed implantation (PSI) occasionally reveals suboptimal dosi-
metric coverage of the gland. Published reports of re-implantation techniques have focused on earlier-generation tech-
niques, including preplanned approaches and stranded seeds. The purpose of this case report is to describe a customizable
approach to perform corrective re-implantation using loose seeds and intraoperative planning technique. 
Material and methods: This case report describes a 63-year-old male with favorable risk prostate adenocarcinoma
receiving PSI. Thirty day post-implant dosimetric evaluation revealed suboptimal coverage of the base of the gland. Us-
ing guidance from post-implant CT-images and real-time planning, the patient received a corrective re-implantation with
intraoperative planning. 
Results: Post-implant dosimetry after re-implantation procedure with intraoperative planning yielded improved tar-
get volume coverage that achieved standard dosimetric criteria. 
Conclusions: Re-implantation as a salvage treatment technique after sub-optimal PSI is a valid treatment option per-
formed with intraoperative real-time planning.
J Contemp Brachyther 2012; 4, 3: 176-181
DOI: 10.5114/jcb.2012.30684 
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Purpose
Standard treatment guidelines for patients with low-risk
prostate cancer include active surveillance, radical pro -
statectomy, external beam radiation therapy and brachy -
the rapy (seeds, High-Dose-Rate: HDR) [1]. Over the past 
several years, transrectal ultrasound guided (TRUS)
brachytherapy with permanent implantation of seeds (PSI)
has proven to be an effective treatment, especially for those
patients with low risk cancers [2,3]. Freedom from bio-
chemical failure is the criterion most commonly used to
measure the effectiveness of a given implantation procedure,
with failure defined as a rise in PSA of 2 ng/mL above the
post-treatment nadir [4]. As PSI techniques have developed
further, it has become increasingly apparent that treatment
success is closely associated with the dosimetric quality
of the implant [5-7]. A post-implant CT scan allows for eval-
uation of implant quality using measures such as the D90
(highest dose in Gy that covers 90% of the prostate target
volume) and the V100 (percentage of prostate target volume
encompassed by 100% of the prescription dose). The dose
to surrounding organs, most notably the urethra and rec-
tum, is also measured.
Post-implant dosimetry sometimes reveals that a portion
of the prostate has been under-dosed. Without proper dose
coverage, the patient may be more likely to experience a re-
currence [8] and thus further treatment options should be
explored. In this scenario, the patient may choose to undergo
a re-implantation procedure whereby the under-dosed 
region of the gland may be targeted with corrective addi-
tion of seeds. However, repeat PSI poses its own set of dif-
ficulties primarily due to the presence of active seeds placed
in the initial procedure; these seeds cannot be well-visuali -
zed on ultrasound [9] and the planning can be complex 
and error-prone. While the previously implanted seeds are
visible on a CT scan, the CT is not directly compatible with
the intraoperative planning software [10,11]. As a result,
the two imaging techniques must be implemented toge ther,
so that the treatment plan for the second implant proper-
ly accounts for the dose already being received by the pa-
tient. 
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Prior reports of corrective re-implantation techniques 
focused on earlier generation techniques, including pre-
planned approaches and stranded seeds [10-13]. Although
intraoperative planning is now available and widely used
[14], there are no published reports that describe corrective
re-implantation using intraoperative planning. In the cur-
rent case report, we describe an approach to perform cor-
rective re-implantation using loose seeds and intraopera-
tive planning.
Material and methods 
The patient in this case report is a 63-year-old male with
favorable risk prostate adenocarcinoma. His tumor was
a clinical Stage I, T1cN0M0, prostate cancer with an elevated
PSA of 2.1 ng/mL and Gleason score 6 (3+3) in 2/12 cores.
The patient had an American Urological Association (AUA)
symptom index (SI) score of 1 and little to no erectile func-
tion prior to treatment. After being offered all treatment op-
tions in a multidisciplinary clinic, the patient decided to un-
dergo PSI. 
Approximately 1 month prior to prostate seed implan-
tation, the patient was imaged via pelvic CT to estimate the
volume of the prostate. The images were transferred to
the Variseed® (Varian Medical Systems, Palo Alto, CA) plan-
ning system. The prostate was delineated by the radiation
oncologist and the total volume (53.4 mL) was used to es-
timate the number of radioactive I-125 seeds for the implant. 
The patient was brought to the operating room (OR) for
seed implantation under general anesthesia in July 2010.
A Foley catheter was inserted to identify the urethra for treat-
ment planning purposes. The patient was positioned in
the dorsal lithotomy position, the perineum was cleansed
and then a TRUS probe was inserted into the rectum and
positioned to visualize the entire prostate. Transverse im-
ages were acquired covering the entire extent of the prostate.
The radiation oncologist contoured the prostate to be us -
ed as a target volume and organs at risk (bladder and rec-
tum). A treatment plan was generated using the Variseed®
software with a goal of delivering a minimum of 145 Gy to
the periphery of the prostate gland. The estimated D90 was
approximately 180 Gy. Treatment guidelines include rec-
tal 1cc doses less than prescription dose and maximum ure-
thral doses less than 150% of the prescription dose. The size
of the prostate gland in the OR was approximately 39 mL.
Sixteen needles and 61 seeds were used to deliver the
desired dose distribution (Figs. 1 and 2). Seed activity of
0.481 mCi was used for the implant. A modified peripher-
al loading technique was used to deliver adequate dose to
the prostate while minimizing dose to the bladder and ure-
thra. Needles were placed using ultrasound guidance and
ultrasound and fluoroscopic imaging were used during seed
deposition. A marker cable was used to assist with defin-
ing the prostate base on fluoroscopy during the PSI pro-
cedure. The depth of the marker cable was verified of
the base slice as identified on ultrasound. Both ultrasound
and fluoroscopy were used throughout the procedure to ver-
ify position relative to the base of the prostate to aid in seed
deposition. 
The patient returned for a post implant imaging study
approximately 30 days after PSI, allowing for edema
of the gland to subside [15]. At this point, the patient re-
ported an AUA SI score of 2, with quality of life score of 2.
The patient was imaged via CT and images were sent to
the treatment planning system for contour delineation and
seed identification. The prostate and rectum were contoured.
Since a Foley catheter was not inserted and the urethra is
not easily identified on CT imaging, a volume called “cen-
tral prostate” was contoured as a surrogate for estimating
urethral doses. Post-implant dosimetry revealed unaccep -
tably low dose coverage (V100, 71.01%; D90, 92.9 Gy).  Re-
view of the images demonstrated that the base was under -
dosed and comparison to the intraoperative images showed
that the base was underestimated on the intraoperative 
images (Figs. 3 and 4).
The option of supplementing dose through a second 
implant was discussed with the patient and the patient was
amenable to this plan. The post implant CT images were re-
imported into the planning system and used as an image
Fig. 1. Needle and seed locations on BK-Standard template
for initial implant
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Fig. 2. TRUS image of dosimetry from intra-operative treat-
ment plan. Contours include prostate, urethra and rectum.
Isodose lines show coverage of 100%, 125% and 150% of
145 Gy prescription dose
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set for the purpose of pre-planning. Despite the limitation
that CT images have no fixed coordinate system relative to
needle positions used in US imaging and that the slice thick-
ness may vary in magnitude from US slice spacing, the ap-
proximate seed locations and quantity of additional seeds
necessary to achieve the desired dose distribution were ap-
proximated using the CT image set (Fig. 5). Based on pre-
liminary planning studies performed in the Variseed®
planning system, it was determined that approximately 
20 additional seeds would be necessary to compensate for
the initially under-dosed region of the gland. 
Results
A hypothetical pre-plan, based on the post-implant CT,
was printed and brought to the OR as a guide for the re-im-
plantation procedure (Fig. 6). The corrective re-implanta-
tion procedure was performed approximately two months
after the date of the initial implant. In the OR, the patient
was set-up in the dorsal lithotomy position as describ ed
above. TRUS imaging was used to identify the gland and
capture transverse images to the planning system. The pro -
state, urethra and rectum were again delineated. Before
a new treatment plan was generated, the previously de-
posited seeds were loaded as a template from the initial plan
and marked as active seeds. Using the printed pre-plan gen-
erated from the post-implant CT as a guide and consider-
ing the initial seed locations, a composite plan was gene -
rated requiring 20 additional seeds deposited through a total
of 12 needles. For plan evaluation, decay of the previous-
ly deposited seeds was not taken into consideration and
the activity per seed on the day of each respective implant,
0.481 mCi, was assigned to all seeds (Fig. 7). The quality
of the implant as judged by dosimetric indicators signifi-
cantly improved after re-implantation judged by CT post
implant dosimetry following the second implant. The V100
improved from 71.01% to 96.88% and the D90 increased from
92.9 Gy to 173.24 Gy. These results were close to the planned
D90 and V100 values of 182.23 Gy and 99.46%, respective-
ly. After re-implantation, the dose received by the urethra
and rectum remained within the acceptable range. Final
post-implant dosimetry was performed 30 days after
the corrective re-implantation (Fig. 8).
Discussion
Although relatively uncommon in high-volume pro-
grams, prostate seed implant (PSI) procedures may result
in sub-optimal dosage identified on post-implant dosime-
try, requiring further treatment decisions to be made. The
options for a suboptimal PSI with lower than adequate dos-
es include a wait-and-see approach, supplemental external
beam radiation therapy to the entire prostate target volume
or a corrective re-implantation procedure to an underdosed
region(s) of the prostate. Each approach carries its own risks,
including deleterious treatment-related side effects and pos-
sible disease recurrence [16]. After being fully informed of his
options, the patient in this case decided to correct the un-
der-dosed region of the prostate through a second PSI pro-
cedure that incorporated intraoperative planning techniques.
As demonstrated by this case, re-implantation may be a pre-
ferred course of action in some cases where a specific region
of the prostate can be identified to place additional seeds.
In this case, the base was underestimated in the original PSI,
so the corrective re-implantation delivered supplemental
seeds to the base.  
Fig. 3. Shows inferior coverage at the base of the prostate
gland following PSI
Fig. 4. Mid-sagittal views of intended coveraged indicated
by TRUS (upper) and achieved coverage as indicated by
30-day post-operative CT (lower) 
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As previously stated, re-implantation presents obstacles
that do not arise in a typical PSI procedure. Due to limita-
tions inherent to the treatment planning technology, it may
be difficult to ascertain the precise location of existing seeds,
thereby making it more challenging to devise an adequate
treatment plan. The approach used here, which incorporated
both the post-implant CT obtained after the original PSI as
well as intraoperative real-time planning proved to be ef-
fective in improving the dosimetric quality of the implant
and ultimately the clinical outcome for the patient. This ap-
proach is flexible, customizable and can be performed us-
ing standard tools available for intraoperatively-planned
brachytherapy with TRUS images.
Prior studies have described re-implantation primarily us-
ing a CT guided pre-planning approach [10,12], but previous
reports did not describe techniques that incorporate intra-
operative planning. For these procedures, a post-implant CT
scan was the primary tool used in creating a treatment plan,
allowing for existing seeds to be visualized and new seeds to
be planned for re-implantation. However, the method does
not afford the same flexibility as the intraoperative method
used in this case. Because the treatment is planned approxi -
mately one month before the actual procedure, the pre-plan-
ning approach has some important limitations. The main chal-
lenge is placing the patient in the exact same position used
during planning; it is often difficult to replicate this position
precisely. Also, there may be changes in prostate volume be-
tween planning and procedure, leading to deviations from
intended seed location and dosimetry. Intraoperative plan-
ning allows for more flexibility such that needle locations and
seed placement can be adjusted as needed during the pro-
cedure and dose distributions may be updated continuously
Fig. 5. Shows use of CT images to calculate approximate location and number of seeds needed for supplemental implant. Appro -
ximate positions on pre-implant plan served as a guide for seed locations during intra-operative planning
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Fig. 6. Planned needle and seed locations for second im -
plant considering seed locations from first implant
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Fig. 7. Intra-operative plan considering seeds from initial
implant 
2
Fig. 8. Post implant dosimetry from both initial and salvage PSI
during the corrective PSI [17-19]. Furthermore, previous stud-
ies have shown that intraoperative planning leads to a clos-
er match between OR and post-implant dosimetry [20]. This
paper thus describes re-implantation utilizing a contempo-
rary technique with real-time planning.
It should be noted that supplemental EBRT is another op-
tion for re-implantation after an unsatisfactory PSI [21]. In
cases where the prostate target volume is routinely under-
dosed, supplemental EBRT may be preferable to corrective
re-implantation. In cases where the patient reports severe
urinary morbidity after the first PSI procedure or when
the maximum dose delivered to the urethra approaches or
exceeds the tolerance level, it may be prudent to avoid re-
implantation. In a situation such as the case presented in this
study, where the area of underdosage is limited to a defined
region, we recommend that corrective re-implantation us-
ing an intraoperative, real-time planning approach be em-
ployed to achieve target cumulative doses.
Patient Follow-up
The patient feels well 1.5 years after the procedure and
is no longer on alpha blocker therapy. His follow-up PSA
testing shows that it is decreased to 0.70 ng/mL, from base-
line value of 2.0 ng/mL.
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Conclusions
Re-implantation as a salvage treatment technique after
sub-optimal prostate seed implantation is a valid treatment
option and is made easier by an intra-operative real time
planning technique. The method described in this paper
of using the post implant CT as a pre-implant planning tool
to estimate seed number and locations and intra-operative
planning for real time feedback of current and planned seed
locations is feasible. This technique may be adapted for oth-
er cases of sub-optimal dosimetry following PSI. Much cau-
tion must be placed on doses to the urethra and rectum fol-
lowing the initial and subsequent implants. Intra-operative
planning allows the user more flexibility in patient posi-
tioning, locating previously deposited seeds and real time
dosimetry of supplemental seed deposition.
References
1. Scherr D, Swindle P, Scardino P. National Comprehensive Can-
cer Network guidelines for the management of prostate can-
cer. Urology 2003; 61: 14-24.
2. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after
prostate brachytherapy with 5-year minimal follow-up: Impor-
tance of patient selection and implant quality. Int J Radiat Oncol
Biol Phys 2003; 57: 645-653. 
3. Hinnen KA, Battermann JJ, van Roermund JG et al. Long-term
biochemical and survival outcome of 921 patients treated with
I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol
Phys 2010; 76: 1433-1438. 
4. Henry AM, Al-Qaisieh B, Gould K et al. Outcomes following
iodine-125 monotherapy for localized prostate cancer: The re -
sults of leeds 10-year single-center brachytherapy experience.
Int J Radiat Oncol Biol Phys 2010; 76: 50-56. 
5. Ash D, Al-Qaisieh B, Bottomley D et al. The correlation bet -
ween D90 and outcome for I-125 seed implant monotherapy
for localised prostate cancer. Radiother Oncol 2006; 79: 185-189. 
6. Potters L, Huang D, Calugaru E et al. Importance of implant
dosimetry for patients undergoing prostate brachytherapy.
Urology 2003; 62: 1073-1077. 
7. Stock RG, Stone NN. Importance of post-implant dosimetry in
permanent prostate brachytherapy. Eur Urol 2002; 41: 434-439. 
8. Nag S, Beyer D, Friedland J et al. American brachytherapy soci-
ety (ABS) recommendations for transperineal permanent bra -
chytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;
44: 789-799.
9. Han BH, Wallner K, Merrick G et al. Prostate brachytherapy
seed identification on post-implant TRUS images. Med Phys
2003; 30: 898-900. 
10. Hughes L, Waterman FM, Dicker AP. Salvage of suboptimal
prostate seed implantation: Reimplantation of underdosed
region of prostate base. Brachytherapy 2005; 4: 163-170. 
11. Keyes M, Pickles T, Agranovich A et al. 125I reimplantation in
patients with poor initial dosimetry after prostate brachyther-
apy. Int J Radiat Oncol Biol Phys 2004; 60: 40-50. 
12. Koutrouvelis P, Hendricks F, Lailas N et al. Salvage reimplan -
tation in patient with local recurrent prostate carcinoma after
brachytherapy with three dimensional computed tomography-
guided permanent pararectal implant. Technol Cancer Res Treat
2003; 2: 339-344. 
13. Bice WS Jr, Freeman JE, Russell LF Jr et al. Use of image coreg-
istration in salvage prostate brachytherapy. Tech Urol 2000; 6:
151-6.
14. Raben A, Sammons S, Sim S et al. Initial comparison of inverse
optimization, modified peripheral technique, and geometric
optimization as real-time intraoperative computer planning
options for permanent seed implantation of the prostate.
Brachytherapy 2007; 6: 238-245. 
15. Waterman FM, Dicker A. Impact of postimplant edema on
V100 and D90 in prostate brachytherapy: Can implant quali-
ty be predicted on Day 0? Int J Radiat Oncol Biol Phys 2002; 53:
610-621.
16. Brachman DG, Thomas T, Hilbe J et al. Failure-free survival
following brachytherapy alone or external beam irradiation
alone for T1-2 prostate tumors in 2222 patients: Results from
a single practice. Int J Radiat Oncol Biol Phys 2000; 48: 111-117. 
17. Matzkin H, Kaver I, Bramante-Schreiber L et al. Comparison
between two iodine-125 brachytherapy implant techniques:
Pre-planning and intra-operative by various dosimetry quali-
ty indicators. Radiother Oncol 2003; 68: 289-294. 
18. Matzkin H, Kaver I, Stenger A et al. Iodine-125 brachytherapy
for localized prostate cancer and urinary morbidity: A prospec-
tive comparison of two seed implant methods-preplanning
and intraoperative planning. Urology 2003; 62: 497-502. 
19. Stock RG, Stone NN, Lo YC. Intraoperative dosimetric repre-
sentation of the real-time ultrasound-guided prostate implant.
Tech Urol 2000; 6: 95-98. 
20. Stone NN, Hong S, Lo YC et al. Comparison of intraoperative
dosimetric implant representation with postimplant dosime-
try in patients receiving prostate brachytherapy. Brachytherapy
2003; 2: 17-25. 
21. Sahgal A, Roach M. Permanent prostate seed brachytherapy:
a current perspective on the evolution of the technique and its
application. Nat Clin Pract Urol 2007; 4: 657-670.
Re-implantation with intraoperative planning 181
